Previous close | 253.89 |
Open | 0.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | N/A |
Market cap | 6.521B |
Beta (5Y monthly) | 1.93 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.61 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV) The board of XVIVO Perfusion AB (publ) ("XVIVO") has appointed Christoffer Rosenblad as CEO.
XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) XVIVO Perfusion AB (publ) ("XVIVO") has today on November 30, 2022, completed the acquisition of all shares in XVIVO S.rl., acquired from XVIVO S.r.l., whose operations were transferred from Avionord S.r.l.
XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV) XVIVO continues to build and strengthen the company.